One such medication is naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA) that blocks the effects of opioids on the gastrointestinal tract. Naloxegol has been shown to be effective in managing OIC in clinical trials and has been approved by the FDA for use in patients with chronic non-cancer pain. Other medications in this class include methylnaltrexone and naloxone, which are also approved for the treatment of Opioid Induced Side Effects Treatment Market.
In addition to pharmacological options, there are also non-pharmacological approaches to managing OIC. These include dietary changes, increased fluid intake, and physical activity. These interventions are often used in conjunction with pharmacological therapies to improve patient outcomes.
Read More:
https://knackersblogger.blogspot.com/2023/03/global-opioid-induced-side-effects.html
